Opendata, web and dolomites

Cells in Matrix SIGNED

Cells in Matrix – an innovative 3D model for R&D of Diabetes

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 Cells in Matrix project word cloud

Explore the words cloud of the Cells in Matrix project. It provides you a very rough idea of what is the project "Cells in Matrix" about.

ing    medications    entry    plans    predictability    425    insulin    identification    fti    global    ingelheim    commercialization    investment    629    endusers    vitro    therapeutics    poor    molecules    3d    validation    11    pancreas    commercial    screening    pharmacokinetics    prevalence    drugs    human    reaching    innovative    fundraising    least    betalin    adults    significantly    keeps    develops    sourced    rendering    disruptive    accelerating    receives    20    tool    matrix    share    cagr    added    people    shelf    rate    cells    2019    function    culture    compound    micro    life    penetration    mode    diabetes    saving    creates    engineered    discovery    action    hampered    reliability    model    prediction    pharma    industry    organ    revenues    academia    emp    million    offers    companies    constant    toxicology    drug    reached    adult    till       compounds    direct    2045    extended    kugelmeiers    gained    market    external    cell    2017    producing    13    90    stakeholders    boehringer    demand    billion    x4   

Project "Cells in Matrix" data sheet

The following table provides information about the project.

Coordinator
BETALIN THERAPEUTICS LTD 

Organization address
address: 3 MENACHEM BEGIN
city: RAMAT GAM
postcode: 5268101
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Israel [IL]
 Total cost 3˙340˙842 €
 EC max contribution 2˙640˙417 € (79%)
 Programme 1. H2020-EU.3. (PRIORITY 'Societal challenges)
2. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies)
 Code Call H2020-EIC-FTI-2018-2020
 Funding Scheme IA
 Starting year 2020
 Duration (year-month-day) from 2020-03-01   to  2022-08-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    BETALIN THERAPEUTICS LTD IL (RAMAT GAM) coordinator 1˙233˙750.00
2    UNIVERSITAT ZURICH CH (ZURICH) participant 527˙967.00
3    TECHNISCHE UNIVERSITAET DRESDEN DE (DRESDEN) participant 478˙125.00
4    KUGELMEIERS AG CH (ERLENBACH) participant 400˙575.00

Map

 Project objective

The demand for diabetes drugs keeps increasing as adult Diabetes prevalence reached 425 million people in 2017 (1 in 11 adults) and is estimated to rise to 629 million till 2045. The market of Diabetes drugs is expected to reach €80.5 Billion in 2019 while the investment in Diabetes drug development is ~ €4 Billion (CAGR of 13%). There is a constant need for more effective diabetes medications, hampered by the poor predictability of the current systems for identification of lead compounds during drug discovery. The failure rate of new drugs development is about 90% and the cost for reaching the market with a new drug is ~ €1 Billion. Cells in Matrix Project develops an innovative 3D model for R&D of Diabetes Drugs , an Engineered Micro Pancreas (EMP) based on organ-derived 3D cell culture and human sourced insulin producing cells as an innovative tool for accelerating and cost reduction of Diabetes drug development. EMP system offers significantly extended shelf life and function for in-depth studies of drug molecules mode of action, validation, toxicology and in vitro pharmacokinetics, rendering higher prediction reliability. Cells in Matrix disruptive technology creates market added value to all the stakeholders, especially pharma industry, by improving compound screening at least X4 (from 5% rate of success today to at least 20%), resulting in cost saving that could reach €100 million per innovative new drug development. The project receives strong interest from stakeholders and plans immediate commercialization of the product to direct endusers, including academia and pharma companies, such as Boehringer Ingelheim. The FTI funding will enable market entry and validation & support external fundraising for the wider penetration of the global drug discovery market. Betalin Therapeutics and Kugelmeiers, the project commercial leading partners will share the growth and revenues gained by its commercial success.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "CELLS IN MATRIX" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "CELLS IN MATRIX" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.;H2020-EU.2.1.)

GoSafe (2019)

Restoring complete sensory ability for natural walking of amputees

Read More  

BIOSNAP (2019)

SMART, SUSTAINABLE & CONVENIENT UNIT DOSE PACKAGING

Read More  

GIoT (2019)

Nano-satellites based Global Infrastructure to Enable IoT/M2M Networks - GIoT (Global IoT)

Read More